Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 450

1.

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.

Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, Giannini EG, Grimaudo S, Maria Pipitone R, Craxì A.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14250. [Epub ahead of print]

PMID:
31507057
2.

Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study).

Calvaruso V, Bronte F, Ferraro D, Reina G, Conte E, Rini F, Magro B, Petta S, Di Marco V, Craxì A.

Liver Int. 2019 Dec;39(12):2240-2243. doi: 10.1111/liv.14242. Epub 2019 Sep 20.

PMID:
31502755
3.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
4.

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30886-9. doi: 10.1016/j.cgh.2019.08.011. [Epub ahead of print]

PMID:
31419571
5.

NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients.

Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F.

Cells. 2019 Jul 2;8(7). pii: E666. doi: 10.3390/cells8070666.

6.

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.

Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.

Liver Int. 2019 Sep;39(9):1742-1754. doi: 10.1111/liv.14167. Epub 2019 Jun 26.

7.

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Wai-Sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart JB, Lai-Hung Wong G, Vergniol J, Wing-Hung Chan A, Giannetti A, Merrouche W, Lik-Yuen Chan H, Le-Bail B, Lombardi R, Guastella S, Craxì A, de Ledinghen V.

Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.

PMID:
31169533
8.

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience.

Calvaruso V, Cacciola I, Licata A, Madonia S, Benigno R, Petta S, Bronte F, Conte E, Malizia G, Bertino G, Distefano M, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Davì A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Portelli V, Prestileo T, Averna A, Iacobello C, Mondello L, Scifo G, Russello M, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; RESIST-HCV (Rete Sicilia Selezione Terapia–HCV).

Am J Gastroenterol. 2019 Aug;114(8):1275-1282. doi: 10.14309/ajg.0000000000000266.

PMID:
31135449
9.

Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group.

Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A.

Dig Liver Dis. 2019 Jul;51(7):915-921. doi: 10.1016/j.dld.2019.03.033. Epub 2019 Apr 25. Review.

10.

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group.

J Hepatol. 2019 Aug;71(2):265-273. doi: 10.1016/j.jhep.2019.03.027. Epub 2019 Apr 6.

PMID:
30959157
11.

Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.

Buzzetti E, Petta S, Manuguerra R, Luong TV, Cabibi D, Corradini E, Craxì A, Pinzani M, Tsochatzis E, Pietrangelo A.

Liver Int. 2019 Jul;39(7):1325-1334. doi: 10.1111/liv.14096. Epub 2019 Mar 27.

PMID:
30851216
12.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
13.

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.

Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A.

Sci Rep. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0.

14.

Real life experiences in HCV management in 2018.

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Review.

PMID:
30582384
15.

FibroScan Detects Cardiovascular Damage in Patients With NAFLD.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2018 Dec 8. pii: S1542-3565(18)31254-0. doi: 10.1016/j.cgh.2018.11.011. [Epub ahead of print]

PMID:
30528844
16.

Expert opinion on managing chronic HCV in patients with cardiovascular disease.

Vassalle C, Petta S, Pepe A, Craxi A, Bondin M, Cacoub P.

Antivir Ther. 2018;23(Suppl 2):35-46. doi: 10.3851/IMP3248. Review.

17.

Viral resistance in HCV infection.

Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A.

Curr Opin Virol. 2018 Oct;32:115-127. doi: 10.1016/j.coviro.2018.10.005. Epub 2018 Nov 12. Review.

PMID:
30439589
18.

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

Di Marco V, Alberti A, Angarano G, Colombo M, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P, Craxì A.

Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):7024-7033. doi: 10.26355/eurrev_201810_16174.

19.

Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience.

Alberti A, Angarano G, Colombo M, Craxì A, Di Marco V, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P.

Clin Res Hepatol Gastroenterol. 2019 Apr;43(2):190-200. doi: 10.1016/j.clinre.2018.09.007. Epub 2018 Oct 28.

20.

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.

Lampertico P, Brunetto MR, Craxì A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group.

J Viral Hepat. 2019 Jan;26(1):118-125. doi: 10.1111/jvh.12999. Epub 2018 Dec 11.

PMID:
30187599
21.

Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study.

Novo G, Macaione F, Giannitrapani L, Minissale MG, Bonomo V, Indovina F, Petta S, Soresi M, Montalto G, Novo S, Craxi A, Licata A.

Aliment Pharmacol Ther. 2018 Oct;48(7):740-749. doi: 10.1111/apt.14934. Epub 2018 Aug 10.

PMID:
30095177
22.

Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?

Cabibbo G, Celsa C, Cammà C, Craxì A.

Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21. Review.

PMID:
29935096
23.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

24.

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C).

Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y.

25.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H.

J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

26.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
27.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

PMID:
29802949
28.

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV).

Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.

PMID:
29655836
29.

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.

Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, Buscemi S.

Liver Int. 2018 Nov;38(11):2060-2068. doi: 10.1111/liv.13743. Epub 2018 May 7.

PMID:
29577560
30.

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.

Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP.

J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875. Review.

PMID:
29508946
31.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
32.

Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.

Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, Zafonte R, Cabibi D, Cammà C, Di Marco V, Licata A, Magliozzo F, Marchesini G, Merlino G, Craxì A, Pinto A.

Cardiovasc Diabetol. 2018 Feb 16;17(1):28. doi: 10.1186/s12933-018-0670-7.

33.

Is global elimination of HCV realistic?

Calvaruso V, Petta S, Craxì A.

Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Review.

PMID:
29427499
34.

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.

35.

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.

Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagiuoli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G.

Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18.

PMID:
29193356
36.

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.

Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C.

PLoS One. 2017 Nov 21;12(11):e0186136. doi: 10.1371/journal.pone.0186136. eCollection 2017.

37.

Current and future challenges in HCV: insights from an Italian experts panel.

Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A.

Infection. 2018 Apr;46(2):147-163. doi: 10.1007/s15010-017-1093-1. Epub 2017 Nov 2. Review.

PMID:
29098647
38.

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.

Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E.

Liver Int. 2018 Apr;38(4):715-723. doi: 10.1111/liv.13612. Epub 2017 Nov 3.

39.

HBV recurrence after HCV clearance on DAAs: Sometimes they come back.

Calvaruso V, Craxì A.

J Hepatol. 2017 Nov;67(5):898-901. doi: 10.1016/j.jhep.2017.08.017. Epub 2017 Aug 31. No abstract available.

PMID:
28864279
40.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E.

Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.

41.

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Aliment Pharmacol Ther. 2017 Oct;46(7):688-695. doi: 10.1111/apt.14256. Epub 2017 Aug 9.

42.

Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.

Petta S, Wong VW, Cammà C, Hiriart JB, Wong GL, Vergniol J, Chan AW, Di Marco V, Merrouche W, Chan HL, Marra F, Le-Bail B, Arena U, Craxì A, de Ledinghen V.

Aliment Pharmacol Ther. 2017 Sep;46(6):617-627. doi: 10.1111/apt.14219. Epub 2017 Jul 27.

43.

Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.

Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group.

Hepatology. 2017 Dec;66(6):1814-1825. doi: 10.1002/hep.29399. Epub 2017 Oct 30.

44.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A.

Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.

PMID:
28741298
45.

Can we prevent and modify cardiometabolic disorders by controlling HCV infection?

Petta S, Craxi A.

Gut. 2018 Mar;67(3):403-404. doi: 10.1136/gutjnl-2017-314505. Epub 2017 Jul 13. No abstract available.

PMID:
28706079
46.

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.

Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V.

J Viral Hepat. 2018 Jan;25(1):72-79. doi: 10.1111/jvh.12754. Epub 2017 Aug 9.

PMID:
28703895
47.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

48.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

49.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
50.

Primary Biliary Cholangitis: advances in management and treatment of the disease.

Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L, Vespasiani Gentilucci U, Gardini I, Gasbarrini A, Kruger P, Mennini FS, Ronco V, Lanati E, Canonico PL, Alvaro D.

Dig Liver Dis. 2017 Aug;49(8):841-846. doi: 10.1016/j.dld.2017.05.001. Epub 2017 May 8.

Supplemental Content

Support Center